Key result
The mSAVA sequence successfully generated high-resolution, co-registered 3D whole-heart T1 and T2 maps in approximately 8 to 10 minutes, showing consistent findings with conventional 2D sequences and late gadolinium enhancement.
Why the study?
Clinical adoption of 3D myocardial T1 and T2 mapping is limited by long scan duration, while current clinical tools rely primarily on 2D breath-hold sequences.
Does the mSAVA 3D free-breathing sequence provide accurate and simultaneous myocardial T1 and T2 mapping compared to conventional 2D sequences?
Does the mSAVA 3D free-breathing sequence provide accurate and simultaneous myocardial T1 and T2 mapping compared to conventional 2D sequences?
The mSAVA sequence enables fast, free-breathing, 3D simultaneous whole-heart T1 and T2 mapping with comparable accuracy to conventional 2D breath-hold techniques.
Supports efficient 3D cardiac mapping feasibility; leaves open prospective validation before clinical adoption.
Quantitative myocardial tissue characterization with T1 and T2 parametric mapping can provide an accurate and complete assessment of tissue abnormalities across a broad range of cardiomyopathies. However, current clinical T1 and T2 mapping tools rely predominantly on two-dimensional (2D) breath-hold sequences. Clinical adoption of three-dimensional (3D) techniques is limited by long scan duration. The aim of this study is to develop and validate a time-efficient 3D free-breathing simultaneous T1 and T2 mapping sequence using multi-parametric SAturation-recovery and Variable-flip-Angle (mSAVA). mSAVA acquires four volumes for simultaneous whole-heart T1 and T2 mapping. We validated mSAVA using simulations, phantoms, and in-vivo experiments at 3T in 11 healthy subjects and 11 patients with diverse cardiomyopathies. T1 and T2 values by mSAVA were compared with modified Look-Locker inversion recovery (MOLLI) and gradient and spin echo (GraSE), respectively. The clinical performance of mSAVA was evaluated against late gadolinium enhancement (LGE) imaging in patients. Phantom T1 and T2 by mSAVA showed a strong correlation to reference sequences (R2 = 0.98 and 0.99). In-vivo imaging with an imaging resolution of 1.5 × 1.5 × 8 mm3 could be achieved. Myocardial T1 and T2 of healthy subjects by mSAVA were 1310 ± 46 and 44.6 ± 2.0 ms, respectively, with T1 standard deviation higher than MOLLI (105 ± 12 vs 60 ± 16 ms) and T2 standard deviation lower than GraSE (4.5 ± 0.8 vs 5.5 ± 1.0 ms). mSAVA T1 and T2 maps presented consistent findings in patients undergoing LGE. Myocardial T1 and T2 of all patients by mSAVA were 1421 ± 79 and 47.2 ± 3.3 ms, respectively. mSAVA is a fast 3D technique promising for clinical whole-heart T1 and T2 mapping.
No takes yet. Share an insight, caveat, or question.
Si et al. (2024) studied Cardiomyopathies (n=32). mSAVA sequence vs. MOLLI and GraSE sequences was evaluated on Myocardial T1 and T2 mapping values. The mSAVA sequence successfully generated high-resolution, co-registered 3D whole-heart T1 and T2 maps in approximately 8 to 10 minutes, showing consistent findings with conventional 2D sequences and late gadolinium enhancement.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: